Bayer Past Earnings Performance
Past criteria checks 0/6
Bayer has been growing earnings at an average annual rate of 14.5%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 4.6% per year.
Key information
14.5%
Earnings growth rate
14.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 4.6% |
| Return on equity | -8.9% |
| Net Margin | -6.2% |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Bayer makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 47,637 | -2,941 | 14,714 | 5,835 |
| 30 Sep 23 | 47,775 | -3,667 | 14,881 | 5,511 |
| 30 Jun 23 | 48,714 | 1,448 | 15,565 | 6,175 |
| 31 Mar 23 | 50,489 | 3,037 | 16,143 | 6,285 |
| 31 Dec 22 | 50,739 | 4,150 | 16,036 | 6,168 |
| 30 Sep 22 | 49,857 | 4,700 | 15,993 | 5,884 |
| 30 Jun 22 | 48,357 | 4,239 | 15,413 | 5,681 |
| 31 Mar 22 | 46,392 | 2,202 | 14,936 | 5,582 |
| 31 Dec 21 | 44,081 | 1,000 | 14,531 | 5,326 |
| 30 Sep 21 | 42,958 | 222 | 12,479 | 3,449 |
| 30 Jun 21 | 41,683 | -7,565 | 13,772 | 5,010 |
| 31 Mar 21 | 40,883 | -14,849 | 13,524 | 4,780 |
| 31 Dec 20 | 41,400 | -15,569 | 13,886 | 4,884 |
| 30 Sep 20 | 42,155 | -15,995 | 15,174 | 7,215 |
| 30 Jun 20 | 43,479 | -7,303 | 13,820 | 5,100 |
| 31 Mar 20 | 44,138 | 2,631 | 14,594 | 5,267 |
| 31 Dec 19 | 43,545 | 2,391 | 14,801 | 5,282 |
| 30 Sep 19 | 43,150 | -1,530 | 15,360 | 5,196 |
| 30 Jun 19 | 42,581 | 287 | 15,241 | 5,082 |
| 31 Mar 19 | 39,856 | 557 | 14,366 | 4,978 |
| 31 Dec 18 | 36,742 | 1,374 | 13,238 | 4,701 |
| 30 Sep 18 | 34,983 | 6,027 | 13,276 | 4,525 |
| 30 Jun 18 | 33,747 | 3,237 | 12,480 | 4,434 |
| 31 Mar 18 | 34,473 | 3,486 | 12,579 | 4,254 |
| 31 Dec 17 | 35,015 | 3,249 | 12,689 | 4,272 |
| 30 Sep 17 | 35,242 | 3,087 | 12,878 | 4,381 |
| 30 Jun 17 | 35,475 | 3,924 | 12,949 | 4,347 |
| 31 Mar 17 | 32,769 | 3,991 | 12,448 | 4,305 |
| 31 Dec 16 | 34,943 | 3,743 | 12,686 | 4,321 |
| 30 Sep 16 | 37,405 | 3,837 | 12,959 | 4,299 |
| 30 Jun 16 | 40,151 | 3,971 | 13,327 | 4,291 |
| 31 Mar 16 | 46,146 | 4,210 | 14,110 | 4,339 |
| 31 Dec 15 | 46,085 | 4,025 | 14,250 | 4,207 |
| 30 Sep 15 | 45,592 | 3,616 | 14,145 | 4,020 |
| 30 Jun 15 | 44,555 | 3,429 | 13,796 | 3,852 |
| 31 Mar 15 | 42,780 | 3,206 | 13,144 | 3,665 |
| 31 Dec 14 | 41,339 | 3,326 | 12,576 | 3,535 |
| 30 Sep 14 | 40,435 | 3,569 | 11,878 | 3,642 |
| 30 Jun 14 | 40,111 | 3,501 | 11,898 | 3,558 |
| 31 Mar 14 | 40,243 | 3,425 | 12,131 | 3,495 |
| 31 Dec 13 | 40,157 | 3,189 | 12,195 | 3,407 |
| 30 Sep 13 | 40,129 | 3,100 | 12,513 | 3,104 |
| 30 Jun 13 | 40,147 | 2,883 | 12,493 | 3,063 |
Quality Earnings: BAYZ.F is currently unprofitable.
Growing Profit Margin: BAYZ.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BAYZ.F is unprofitable, but has reduced losses over the past 5 years at a rate of 14.5% per year.
Accelerating Growth: Unable to compare BAYZ.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BAYZ.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: BAYZ.F has a negative Return on Equity (-8.89%), as it is currently unprofitable.